WO2023041524 - COMPOSITIONS AND METHODS FOR TREATING SYNUCLEINOPATHIES
National phase entry:
Publication Number
WO/2023/041524
Publication Date
23.03.2023
International Application No.
PCT/EP2022/075402
International Filing Date
13.09.2022
Title **
[English]
COMPOSITIONS AND METHODS FOR TREATING SYNUCLEINOPATHIES
[French]
COMPOSITIONS ET MÉTHODES DE TRAITEMENT DES SYNUCLÉINOPATHIES
Applicants **
H. LUNDBECK A/S
Ottiliavej 9
2500 Valby, DK
Inventors
NIELSEN SØDERBERG, Josefine
c/o H. Lundbeck A/S
Ottiliavej 9
2500 Valby, DK
KALLUNKI, Pekka
c/o H. Lundbeck A/S
Ottiliavej 9
2500 Valby, DK
BUUR, Louise
c/o H. Lundbeck A/S
Ottiliavej 9
2500 Valby, DK
LARSEN, Frank
c/o H. Lundbeck A/S
Ottiliavej 9
2500 Valby, DK
PARSHAD, Henrik Rajesh Kumar
c/o H. Lundbeck A/S
Ottiliavej 9
2500 Valby, DK
MARKUSSEN, Anne Sofie
c/o H. Lundbeck A/S
Ottiliavej 9
2500 Valby, DK
MANNING, Mark Cornell
4630 Sorrel Lane
Johnstown, Colorado 80534, US
KATAYAMA, Derrick Spencer
6773 Flintlock Rd
Timnath, Colorado 80547, US
GAUDEN, Magdalena
c/o Lonza Biologics plc
228 Bath Road
Slough
Berkshire SL1 4DX, GB
SMITH, John
c/o Lonza Biologics plc
228 Bath Road
Slough
Berkshire SL1 4DX, GB
Priority Data
EP21197120
16.09.2021
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 3350 | |
| EPO | Filing, Examination | 22590 | |
| Japan | Filing | 591 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 10210 |
Total: 37316 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present invention relates to stable and low viscosity liquid pharmaceutical compositions comprising antibodies binding to human alpha synuclein and to methods for use of antibodies binding to human alpha synuclein for treating synucleinopathies or prodromal synucleinopathy, incl. suitable doses and/or dosing regimens. These antibodies for use in treatment of synucleinopathies or prodromal synucleinopathy may be formulated in the stable and low viscosity liquid pharmaceutical compositions of the invention.[French]
La présente invention concerne des compositions pharmaceutiques liquides stables et à faible viscosité comprenant des anticorps se liant à l'alpha synucléine humaine et des méthodes d'utilisation d'anticorps se liant à l'alpha synucléine humaine pour traiter des synucléinopathies ou une synucléinopathie prodromique, y compris des doses et/ou des schémas posologiques appropriés. Ces anticorps destinés à être utilisés dans le traitement de synucléinopathies ou d'une synucléinopathie prodromique peuvent être formulés dans les compositions pharmaceutiques liquides stables et à faible viscosité de l'invention.